NLM Digital Collections

Search

Start Over Subjects Medicare Part D -- economics ✖Remove constraint Subjects: Medicare Part D -- economics Subjects Prescription Drugs -- economics ✖Remove constraint Subjects: Prescription Drugs -- economics Copyright Public domain ✖Remove constraint Copyright: Public domain

1. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

2. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

4. A comparison of brand-name drug prices among selected federal programs

Author(s):
Baker, Colin, author
Laughery, Scott, author
Patel, Yash, author
Publication:
[Washington, DC] : Congressional Budget Office, February 2021
Subject(s):
Drug Costs -- statistics & numerical data
Government Programs -- economics
Medicaid -- economics
Federal Government
Medicare Part D -- economics
Prescription Drugs -- economics
United States
United States. Department of Defense.
United States. Department of Veterans Affairs.

6. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Economics, Pharmaceutical -- statistics & numerical data
Economics, Pharmaceutical -- trends
Forecasting
Prescription Drugs -- economics
Humans
United States

7. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, September 19, 2023
Subject(s):
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States